Table 3.
Correlation between expression of molecules (ERCC1, beclin-1, and GRP78) and clinicopathologic characteristics
| ERCC1 |
Beclin-1 |
GRP78 |
||||
|---|---|---|---|---|---|---|
| High | p value | High | p value | High | p value | |
| All cases | 21 | 27 | 21 | |||
| Smoking | ||||||
| Never-smoker:smoker | 3:18 | 1 | 5:22 | 1 | 5:16 | 0.147 |
| Pathology | ||||||
| SqCC:non-SqCC | 14:7 | 1 | 20:11 | 1 | 12:9 | 0.262 |
| Histologic differentiation | ||||||
| MD:PD | 14:7 | 1 | 19:8 | 0.115 | 13:8 | 1 |
| Stage | ||||||
| T1, 2:T3, 4 | 16:5 | 0.021 | 19:12 | 0.619 | 14:7 | 0.447 |
| N0:N1, 2, 3 | 3:18 | 0.739 | 4:23 | 1 | 4:17 | 0.277 |
| IIB, IIIA:IIIB | 17:4 | 0.652 | 21:6 | 1 | 16:5 | 1 |
| Tumor response | ||||||
| CR + PR:SD + PD | 15:6 | 0.685 | 18:9 | 1 | 14:7 | 1 |
Values are presented as number.
ERCC1, excision repair cross-complementation group 1; GRP78, glucose-regulated protein of molecular mass 78; SqCC, squamous cell carcinoma; MD, moderately differentiated; PD, poorly differentiated; CR, complete response; PR, partial response.